In Vitro Antimicrobial Activities of Fusidic Acid and Retapamulin against Mupirocin- and Methicillin-Resistant Staphylococcus aureus
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: The in vitro activities of retapamulin and fusidic acid against clinical isolates of mupirocin-resistant and methicillin- resistant Staphylococcus aureus (MRSA) from Korea are not well understood. Objective: This study aimed to determine the activities of retapamulin and fusidic acid against clinical isolates of mupirocin-resistant MRSA. Methods: Clinical isolates of mupirocin-resistant MRSA were collected from two tertiary hospitals. The minimal inhibitory concentrations of mupirocin, fusidic acid, and retapamulin were determined using agar dilution method. Polymerase chain reaction was used to confirm the identity of the species and the presence of resistance genes. Pulsed-field gel electrophoresis (PFGE) patterns of chromosomal DNA were used to determine the genetic similarity of high-level mupirocin-resistant isolates. Results: Of the 497 MRSA isolates tested, 22 (4.4%) were mupirocin-resistant. Of these, 9 (1.8%) and 13 (2.6%) had high-level and low-level mupirocin resistance, respectively. Analysis of the PFGE patterns of the high-level mupirocin-resistant MRSA isolates identified five clusters. All 13 of the low-level mupirocin-resistant isolates were resistant to fusidic acid but susceptible to retapamulin. However, among the 9 high-level mupirocin-resistant isolates, 56% were resistant to fusidic acid, and all were susceptible to retapamulin. Conclusion: Retapamulin is highly active in vitro against Korean clinical isolates of high-level mupirocinand methicillin-resistant Staphylococcus aureus with different genetic backgrounds. Fusidic acid is more active against high-level mupirocin-resistant MRSA than low-level mupirocin- resistant MRSA.
Abstract
Background: The in vitro activities of retapamulin and fusidic acid against clinical isolates of mupirocin-resistant and methicillin- resistant Staphylococcus aureus (MRSA) from Korea are not well understood. Objective: This study aimed to determine the activities of retapamulin and fusidic acid against clinical isolates of mupirocin-resistant MRSA. Methods: Clinical isolates of mupirocin-resistant MRSA were collected from two tertiary hospitals. The minimal inhibitory concentrations of mupirocin, fusidic acid, and retapamulin were determined using agar dilution method. Polymerase chain reaction was used to confirm the identity of the species and the presence of resistance genes. Pulsed-field gel electrophoresis (PFGE) patterns of chromosomal DNA were used to determine the genetic similarity of high-level mupirocin-resistant isolates. Results: Of the 497 MRSA isolates tested, 22 (4.4%) were mupirocin-resistant. Of these, 9 (1.8%) and 13 (2.6%) had high-level and low-level mupirocin resistance, respectively. Analysis of the PFGE patterns of the high-level mupirocin-resistant MRSA isolates identified five clusters. All 13 of the low-level mupirocin-resistant isolates were resistant to fusidic acid but susceptible to retapamulin. However, among the 9 high-level mupirocin-resistant isolates, 56% were resistant to fusidic acid, and all were susceptible to retapamulin. Conclusion: Retapamulin is highly active in vitro against Korean clinical isolates of high-level mupirocinand methicillin-resistant Staphylococcus aureus with different genetic backgrounds. Fusidic acid is more active against high-level mupirocin-resistant MRSA than low-level mupirocin- resistant MRSA.
참고문헌 (20)
- Yun HJ, "Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital", J Antimicrob Chemother, 51, pp.619~623 (2003)
- Yoo JI, "Clonal dissemination and mupA gene polymorphism of mupirocin-resistant Staphylococcus aureus isolates from long-term-care facilities in South Korea", Antimicrob Agents Chemother, 50, pp.365~367 (2006)
- 양진아, "Molecular Analysis of Isoleucyl-tRNA Synthetase Mutations in Clinical Isolates of Methicillin-Resistant Staphylococcus aureus with Low-Level Mupirocin Resistance", Journal of Korean Medical Science, 21(5), pp.827~832 (2006), 대한의학회
- Baek YS, "Fusidic acid and mupirocin resistance in Staphylococcus aureus isolated from infected skin wounds in Korean patients", Korean J Dermatol, 64(Suppl), pp.284~ (2012)
- Chaves F, "Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of Staphylococcus aureus from nasal samples", J Clin Microbiol, 42, pp.822~824 (2004)
- Hasani A, "Methicillin resistant and susceptible Staphylococcus aureus: appraising therapeutic approaches in the Northwest of Iran", Iran J Microbiol, 5, pp.56~62 (2013)
- Rahman M, "Mupirocin-resistant Staphylococcus aureus", Lancet, 2, pp.387~388 (1987)
- 박세영, "The Prevalence, Genotype and Antimicrobial Susceptibility of High- and Low-Level Mupirocin Resistant Methicillin-Resistant Staphylococcus aureus", Annals of Dermatology, 24(1), pp.32~38 (2012), 대한피부과학회
- Simor AE, "Mupirocin-resistant, methicillin-resistant Staphylococcus aureus strains in Canadian hospitals", Antimicrob Agents Chemother, 51, pp.3880~3886 (2007)
- Ramsey MA, "Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates", Antimicrob Agents Chemother, 40, pp.2820~2823 (1996)
- Janssen DA, "Detection and characterization of mupirocin resistance in Staphylococcus aureus", Antimicrob Agents Chemother, 37, pp.2003~2006 (1993)
- Lee JS, "A longitudinal molecular epidemiologic study of methicillin resistant Staphylococcus aureus (MRSA) isolates from a university hospital", Korean J Infect Dis, 33, pp.32~39 (2001)
- Tenover FC, "Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis:criteria for bacterial strain typing", J Clin Microbiol, 33, pp.2233~2239 (1995)
- Shah M, "High levels of fusidic acid-resistant Staphylococcus aureus in dermatology patients", Br J Dermatol, 148, pp.1018~1020 (2003)
- Howden BP, "Dumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus", Clin Infect Dis, 42, pp.394~400 (2006)
- Farrell DJ, "Characterization of global patterns and the genetics of fusidic acid resistance", Clin Infect Dis, 52(Suppl 7), pp.S487~S492 (2011)
- Traczewski MM, "Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent", Antimicrob Agents Chemother, 52, pp.3863~3867 (2008)
- Woodford N, "In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin", J Antimicrob Chemother, 62, pp.766~768 (2008)
- Candel FJ, "In vitro activity of retapamulin against linezolid and methicillin-resistant Staphylococcus aureus isolates", Rev Esp Quimioter, 24, pp.127~130 (2011)
- Saravolatz LD, "In vitro activity of retapamulin against Staphylococcus aureus resistant to various antimicrobial agents", Antimicrob Agents Chemother, 57, pp.4547~4550 (2013)